SBIR/STTR Research Award
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti
Award amount
$415,078Program and phase
SBIR · Phase IAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NOVATARG, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- J1FSU9JXELE1
- Solicitation number
- PA13-088
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of gt 2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKDpatients. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of gt 2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Biguanides to Treat Type 2 Diabetes
- Novel Biguanides to Treat Type 2 Diabetes
- Novel and Kidney Selective AMPK Activators to Treat Polycystic Kidney Disease
- Novel and Selective AMPK Activator for the Treatment of Hepatocellular Carcinoma
- Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening. Phase
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
6 SBIR/STTR records share this UEI (2013–2018). Reported award amounts total $5,464,327. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services